BioMarin reported an 18% revenue growth in 2024 with a 28.6% operating margin. The company aims for $4 billion in revenue by 2027 and a 40% operating margin by 2026. Voxogo's potential extends beyond ...
BioMarin's has signed the first contract with an insurer in Germany for Roctavian, its recently approved gene therapy for haemophilia A, as it tests out its outcomes-based agreement (OBA ...
BioMarin ist zuversichtlich bezüglich seines ... dass das volle Potenzial von Voxogo nicht vollständig gewürdigt wird. Es gibt viel Fokus auf Achondroplasie. Das ist aber nur die erste Indikation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback